CurrentCapital BluecrossPolicy MP 5.021

Scintimammography and Gamma Imaging of the Breast and Axilla

Defines coverage stance for scintimammography, breast-specific gamma imaging (BSGI)/molecular breast imaging (MBI), and lymphoscintigraphy/hand-held gamma detection for sentinel lymph node localization in breast cancer patients for Capital BlueCross programs.

Policy Summary

PayerCapital Bluecross

PolicyScintimammography and Gamma Imaging of the Breast and Axilla

Policy CodePolicy MP 5.021

Change TypeAdministrative update (no material clinical changes)

Effective DateOct 1, 2025

Next Review Date

Key ActionDocument the radiopharmaceutical and modality used and verify product-specific prior authorization and member benefits when submitting claims.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalBSGI/MBI stance

Medically necessarySLN localization

10-30 mSvACR dose estimate

2.0-2.5 mSvNewer MBI dose

55-82/100k

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Lifetime cancer risk (age 40)

2019-2025Documented history

Coverage Determinations

Coverage stance

Coverage determinations in this policy:

Investigational - Scintimammography/BSGI/MBI: Scintimammography, breast-specific gamma imaging (BSGI), and molecular breast imaging (MBI) are considered investigational in all applications, including as an adjunct to mammography or for staging the axillary lymph nodes.

Insufficient evidence to support net health outcome benefits.

Medically necessary - Lymphoscintigraphy/Hand-held gamma detection: Use of radiopharmaceutical administration and gamma detection (lymphoscintigraphy) for localization of sentinel lymph nodes in individuals with breast cancer may be considered medically necessary.

Supported by trials showing similar survival and reduced morbidity compared with full axillary dissection.

Indication-specific coverage conclusions

Coverage determinations summarized by indication:

Diagnostic adjunct in dense breasts/high-risk screening: For individuals with dense breasts or at high risk, adding scintimammography/BSGI/MBI to mammography increases sensitivity but reduces specificity; evidence is insufficient to demonstrate improvement in net health outcome and radiation exposure must be considered.

Small number of additional cancers detected in some studies; benefit-risk balance uncertain.

Evaluation of indeterminate or suspicious breast lesions: For indeterminate or suspicious breast lesions, BSGI/MBI negative predictive value (reported 83–94%) is not high enough to replace biopsy; evidence is insufficient to demonstrate improved net health outcome.

Biopsy remains the criterion standard given risk of missed malignancy.

Detection of residual tumor after neoadjuvant therapy: BSGI shows pooled sensitivity ~86% and specificity ~69% for detection of residual tumor after neoadjuvant therapy versus histopathology; no evidence of clinical utility or comparative studies demonstrating improved outcomes.

Diagnostic accuracy demonstrated but clinical utility not established.

Surgical planning for breast-conserving therapy: Evidence (retrospective) suggests MRI may identify more patients unsuitable for breast-conserving therapy than BSGI; prospective comparative studies are lacking and evidence is insufficient to show improved net health outcome with BSGI for surgical planning.

Further prospective data needed.

Detection of axillary metastases (BSGI/scintimammography): Meta-analyses find sensitivity and specificity of BSGI for axillary metastases are inadequate to replace surgical nodal evaluation; evidence is insufficient to demonstrate improved net health outcome.

Not a substitute for surgical nodal staging.

Radiopharmaceutical and gamma detection for sentinel lymph node biopsy: Use of radiopharmaceuticals and gamma detection for sentinel lymph node (SLN) localization yields high SLN identification success rates and detection superior to blue dye and comparable to indocyanine green; SLN biopsy provides similar long-term outcomes to full axillary dissection with reduced morbidity and is considered medically necessary.

Sufficient evidence supports improved net health outcome compared with axillary dissection.

The primary radiopharmaceutical used with breast-specific gamma imaging (BSGI) and molecular breast imaging (MBI) is Tc-99m sestamibi. Per the product labeling, Tc-99m sestamibi is indicated for planar imaging as a second-line diagnostic agent after mammography to assist in evaluation of breast lesions in patients with an abnormal mammogram or a palpable mass. The label explicitly states that Tc-99m sestamibi is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and is not an alternative to biopsy. Providers should document the specific radiopharmaceutical used when submitting claims for BSGI/MBI procedures.

Procedure codes identified in the policy as investigational are excluded from coverage and may be denied. The policy lists investigational procedure codes under the heading “Investigational; therefore, not covered,” including HCPCS code S8080 and other procedural entries; use of these investigational codes is not covered.

Administrative updates to the policy were made effective 09/04/2025 to remove the Benefit Variations Section and to update the disclaimer. Providers should reference current product-specific benefit documents for any remaining plan-level variations.

Available diagnostic accuracy studies and a meta-analysis do not demonstrate that scintimammography, BSGI, or MBI improve net health outcomes when used as adjunctive tests. Although adding BSGI/MBI to mammography can increase sensitivity in selected populations, specificity is reduced and any incremental cancer detection must be weighed against additional radiation exposure. For indeterminate or suspicious lesions, reported negative predictive values (range 83–94%) are insufficient compared with biopsy to change management. For detection of residual tumor after neoadjuvant therapy, pooled sensitivity and specificity (pooled sensitivity 86%, pooled specificity 69%) have been reported, but no studies establish clinical utility or demonstrate that these findings improve patient outcomes. Collectively, these data support the conclusion that scintimammography/BSGI/MBI are not established to provide net health benefit as adjunctive testing.

The evidence base for scintimammography, BSGI, and MBI across most diagnostic and treatment indications is insufficient to demonstrate improved net health outcomes. The policy considers these modalities investigational in all applications, including as adjuncts to mammography, for evaluation of indeterminate/suspicious lesions, for surgical planning, and for axillary staging. Where data exist, they show limitations in specificity, limited comparative effectiveness data against current standards, and no demonstrated impact on survival or treatment-related morbidity.

Indications and When Covered

BSGI/MBI/scintimammography for breast imaging

Investigational Indication: Any application of scintimammography, BSGI, or MBI (including adjunct to mammography or axillary staging)

Considered investigational due to insufficient evidence to demonstrate improved net health outcome.

Lymphoscintigraphy / sentinel node localization

Medically Necessary Indication: Preoperative lymphoscintigraphy and/or intraoperative hand-held gamma detection for localization of sentinel lymph nodes in individuals with breast cancer.

Supported by randomized trials (e.g., NSABP B-32) and systematic reviews showing similar survival and reduced morbidity versus axillary dissection.

Diagnostic adjunct to mammography in dense breasts or high-risk screening

Procedure and Diagnosis Codes

Radiopharmaceuticals referencedmixed

Tc-99m sestamibi	Radiopharmaceutical commonly used for BSGI/MBI; FDA labeled for planar imaging as second-line diagnostic after mammography
Tc-99m tilmanocept (Lymphoseek)	Radiopharmaceutical approved for lymph node localization in breast cancer
Tc-99m sulfur colloid	Radiopharmaceutical used for intraoperative sentinel node localization

Investigational; therefore, not coveredHCPCSNot Covered

S8080

Covered when medically necessarymixedCovered

78195
78800
78801
78835
A9500
A9520
A9541

Covered when medically necessary - Diagnosis codes (excerpt)ICD-10Covered

C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
C50.021	Malignant neoplasm of nipple and areola, right male breast
C50.022	Malignant neoplasm of nipple and areola, left male breast
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast
C50.111	Malignant neoplasm of central portion of right female breast
C50.112	Malignant neoplasm of central portion of left female breast
C50.119	Malignant neoplasm of central portion of unspecified female breast
C50.121	Malignant neoplasm of central portion of right male breast

1–10 of 21

1/3

Historically added/removed CPT codes mentioned in policy historyCPT

78830	CPT code previously added (removed later as noted in policy history)
78831	CPT code previously added (removed later as noted in policy history)
78832	CPT code previously added (removed later as noted in policy history)
78835	CPT code added in 2020 and referenced in policy history

Provider Responsibilities and Billing Guidance

Prior Authorization

Product-specific prior authorization

This policy may not apply to all Capital BlueCross products or programs. Product-specific prior authorization requirements and benefit variations may apply; verify plan-specific coverage and prior authorization rules before scheduling services.

Applicable to select Capital Blue Cross programs and products only — verify member’s plan.
FEP PPO: refer to FEP Medical Policy Manual (link in policy).

Prior Authorization

Prior authorization and covered codes

Prior authorization requirements and coverage for the procedures and codes listed in the coding section are determined by the member’s benefit plan and medical necessity. Presence of a code in the coding list does not guarantee coverage. Obtain prior authorization when required by the member’s plan.

Coverage determined by member benefit information and medical necessity.
Not all covered services are eligible for separate reimbursement.

Prior Authorization Requirements

Note

Confirm program-specific rules (e.g., FEP PPO)

Check product-specific rules for prior authorization and policy applicability; some programs (for example, FEP PPO) refer to an external FEP Medical Policy Manual for their coverage rules.

Prior Authorization

Nuclear medicine/gamma imaging coverage depends on benefit and medical necessity

Coverage of nuclear medicine and gamma imaging procedures listed in this policy is subject to medical necessity and member benefit determinations; prior authorization may be required depending on the plan.

Verify prior authorization requirements with the member's benefit plan before scheduling nuclear medicine or gamma imaging services.

Services Not Covered

Use of Tc-99m sestamibi for breast cancer screening or as an alternative to biopsy is not supported. The product label specifies that Tc-99m sestamibi is not indicated for screening, to confirm presence or absence of malignancy, and is not an alternative to tissue diagnosis by biopsy; claims for screening or biopsy-alternative uses may be denied.

Scintimammography, BSGI, and MBI are considered investigational for the majority of diagnostic and treatment indications addressed in this policy. The policy designates these modalities as investigational in all applications and lists investigational procedure codes that are not covered. Providers should expect that claims for these services may be denied when submitted for investigational indications.

Background and Rationale

Scintimammography, BSGI, and MBI are nuclear medicine techniques that image radiotracer uptake in breast tissue using gamma cameras. BSGI and MBI employ breast-dedicated gamma cameras (single- or dual-head) with the detector placed adjacent to a lightly compressed breast to improve spatial resolution compared with conventional planar scintimammography. The most commonly used radiotracer for BSGI/MBI is Tc-99m sestamibi. Lymphoscintigraphy and intraoperative hand-held gamma detection use Tc-99m–labeled colloids or Tc-99m tilmanocept (Lymphoseek) to localize sentinel lymph nodes for biopsy in patients with breast cancer; these techniques are supported as medically necessary for sentinel lymph node localization.

Definitions

BSGI/MBI — Definitions for breast-specific gamma imaging and molecular breast imaging

TermBSGI/MBI

DefinitionBreast-specific gamma imaging (BSGI) and molecular breast imaging (MBI) are breast-dedicated gamma camera techniques that acquire images with the detector adjacent to a lightly compressed breast, using single- or dual-head detectors to increase resolution compared with conventional gamma cameras.

Typical radiopharmaceuticalTechnetium Tc-99m sestamibi is the primary radiopharmaceutical used for BSGI/MBI.

Imaging position/techniquePatient is seated in a position similar to mammography with light breast compression and detector heads immediately next to the breast for higher-resolution images.

Lymphoscintigraphy / Hand-held gamma detection — Definition for sentinel node localization techniques

Term

Policy History

2025-09-04administrative_update

Removed Benefit Variations section and updated the Disclaimer.

2025-09-02coding_update

Administrative update adding new ICD-10 codes effective 2025-10-01.

2025-04-10consensus_review

Consensus review with no change to policy statement; removed CPT codes 78830, 78831, and 78832.

Policy Summary

PayerCapital Bluecross

PolicyScintimammography and Gamma Imaging of the Breast and Axilla

Policy CodePolicy MP 5.021

Change TypeAdministrative update (no material clinical changes)

Effective DateOct 1, 2025

Next Review Date

Key ActionDocument the radiopharmaceutical and modality used and verify product-specific prior authorization and member benefits when submitting claims.

SourceLink

On This Page

Adjunct imaging in dense breasts or high-risk patients: BSGI/MBI/scintimammography may increase cancer detection sensitivity when added to mammography in women with dense breasts or elevated risk but lowers specificity; evidence is insufficient to support routine use as it has not been shown to improve net health outcomes.

Radiation exposure considerations apply.

Evaluation of indeterminate or suspicious breast lesions

Evaluation of indeterminate/suspicious lesions: BSGI/MBI negative predictive value (83–94%) is insufficient compared with biopsy to alter standard management; therefore BSGI/MBI is not a replacement for biopsy in evaluation of indeterminate or suspicious breast lesions.

Compare with other diagnostic modalities (e.g., spot mammography) when considering adjunct testing.

Detection of residual tumor after neoadjuvant therapy

Assessment after neoadjuvant therapy: BSGI demonstrates pooled sensitivity of approximately 86% and pooled specificity of approximately 69% for detecting residual tumor after neoadjuvant therapy versus histopathology; however, no studies show clinical utility or impact on outcomes.

Diagnostic accuracy shown but evidence insufficient to alter management pathways.

Radiopharmaceutical/gamma detection for sentinel lymph node biopsy

Radiopharmaceuticals for sentinel node localization: Radiopharmaceuticals used for lymphoscintigraphy and intraoperative detection include Tc-99m labeled colloids, Tc-99m tilmanocept (Lymphoseek), and Tc-99m sulfur colloid; these agents with gamma detection are effective for sentinel lymph node localization.

Document the radiopharmaceutical and procedural details when submitting claims.

Referenced clinical scenarios where scintimammography and breast-specific gamma imaging have been studied

Documented clinical indications cited in references: Clinical scenarios studied for scintimammography/BSGI/MBI include: adjunct imaging for mammographically dense breasts, evaluation of BI-RADS 4 (indeterminate) lesions, assessment of residual tumor after neoadjuvant chemotherapy, detection of occult breast cancer in high-risk women, and sentinel lymph node mapping.

See referenced literature for study details and diagnostic performance metrics.

Billing Rule

Confirm current CPT/HCPCS/ICD-10 codes before submission

Verify the current CPT/HCPCS/ICD-10 codes prior to claim submission. Coding changes may occur over time and may affect coverage determinations and prior authorization requirements.

This coding list may not be all-inclusive and is subject to change.
Review policy history for recent code additions/removals (see Policy History).

Denial Risk

Investigational procedures not covered

Scintimammography, breast-specific gamma imaging (BSGI), and molecular breast imaging (MBI) are considered investigational in all applications and therefore are not covered. Claims for investigational procedures may be denied.

Scintimammography, BSGI, and MBI: investigational — not covered.
Refer to the coding section for procedure codes listed as investigational (not covered).

Documentation Required

Radiopharmaceutical and modality documentation

Document the specific radiopharmaceutical(s) administered and the imaging modality used for each procedure (for example, Tc-99m sestamibi for BSGI/MBI; Tc-99m–labeled colloids or Tc-99m tilmanocept for lymphoscintigraphy). Include dose, route, injection site, and timing relative to imaging when applicable.

Record radiopharmaceutical name and dose (e.g., Tc-99m sestamibi, Tc-99m sulfur colloid, Tc-99m tilmanocept).
Document imaging modality and technique (e.g., planar imaging, hand-held gamma detection, lymphoscintigraphy).
Include injection site and timing relative to imaging/surgery when applicable.

Prior Authorization

Coverage conditioned on member benefits and medical necessity

Coverage is conditioned on the member’s benefit plan and medical necessity. Even when a service meets medical necessity criteria, prior authorization and member benefits determine final coverage and reimbursement.

Confirm medical necessity and obtain any required prior authorization.
Verify member benefit limitations, exclusions, and reimbursement rules before performing services.

Documentation Required

Clinical documentation guidance

Provide complete clinical documentation to support medical necessity, including relevant imaging and pathology reports, history and physical findings (e.g., palpable mass, abnormal mammogram), prior diagnostic studies, and rationale for use of the requested procedure. Cite applicable practice guidelines and references as needed.

Include prior mammography findings, clinical breast exam results, and any prior biopsy results.
Attach imaging reports, pathology results, and operative notes if applicable.
Reference pertinent guidelines (e.g., SNM practice guidelines) when supporting the request.

Lymphoscintigraphy / Hand-held gamma detection

DefinitionPreoperative lymphoscintigraphy and/or intraoperative hand-held gamma detection is a method of identifying sentinel lymph nodes for biopsy after radiotracer injection, used to localize nodes and guide sentinel lymph node biopsy as an alternative to full axillary lymph node dissection.

Clinical rationaleSeveral randomized trials and systematic reviews (e.g., NSABP B-32, meta-analyses) show sentinel lymph node biopsy has similar survival and regional control but lower morbidity compared with axillary lymph node dissection.

Common practice detailRadiotracer injection followed by preoperative imaging and intraoperative detection with a hand-held gamma probe is used to identify and remove one or more sentinel nodes for staging.

RADIOPHARMACEUTICAL — Definition of radiopharmaceutical

TermRadiopharmaceutical

DefinitionA radioactive chemical or drug that has a specific affinity for a particular body tissue or organ and is used in nuclear medicine to obtain images of structures or to treat radiation-sensitive diseases.

Use casesUsed for diagnostic imaging (e.g., BSGI/MBI with Tc-99m sestamibi) and for localization procedures (e.g., Tc-99m labeled colloids or tilmanocept for lymphoscintigraphy).

Role in policyDocumentation of the radiopharmaceutical and modality is advised when submitting claims for nuclear breast imaging or lymphoscintigraphy.

Breast-specific gamma imaging (BSGI) — Dedicated gamma-camera imaging definition

TermBreast-specific gamma imaging (BSGI)

DefinitionDedicated gamma-camera imaging of the breast using radiotracers such as technetium Tc-99m sestamibi, with detector heads positioned adjacent to a lightly compressed breast to improve spatial resolution and allow comparison with mammography.

Detector variantsMay use single- or dual-head dedicated breast cameras; detectors can be multicrystal arrays (e.g., cesium iodide) to enhance image quality.

Intended application per labelingTc-99m sestamibi is labeled for planar imaging as a second-line diagnostic after mammography to assist in evaluation of breast lesions, not for screening or as an alternative to biopsy.

Lymphoscintigraphy / sentinel node mapping — Definition for preoperative sentinel node mapping

TermLymphoscintigraphy / sentinel node mapping

DefinitionPreoperative nuclear medicine imaging using radiotracers (e.g., Tc-99m labeled colloids or Tc-99m tilmanocept) to identify sentinel lymph nodes for biopsy in breast cancer patients, often followed by intraoperative localization with a hand-held gamma probe.

Evidence baseRandomized trials and meta-analyses support SLN biopsy as providing similar survival and regional control to axillary dissection with reduced surgical morbidity.

Common radiotracersTc-99m pertechnetate-labeled colloids, Tc-99m tilmanocept (Lymphoseek), and Tc-99m sulfur colloid for intraoperative use.

2024-12-27consensus_review

Consensus review with minor editorial updates to the medically necessary statement and removal of NCCN language; coding reviewed with no changes.

2024-01-19administrative_update

Administrative update adding clinical benefit information.

2022-11-29consensus_review

Consensus review added 'breast specific' to gamma detection statement per BCBSA and updated references; no coding changes.

2021-10-08consensus_review

Consensus review added NCCN statement and updated FEP, regulatory status, rationale, and references; no coding changes.

2020-01-01administrative_update

Administrative update adding new 2020 CPT codes (including 78830, 78831, 78832, and 78835).

2019-09-26consensus_review

Consensus review with coding and a complete literature review; no changes to policy statements.

2019-04-01administrative_update

Administrative update: coding reviewed and updated.

2019-02-01consensus_reviewLatest

Consensus review conducted; policy statements unchanged.